ArticleBioactive materials2025
Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Amphiphilic Covalent Organic Framework for Efficient DHT Adsorption and Androgenetic Alopecia Treatment via Spectral Technology.Molecules (Basel, Switzerland) · 2026Article
- Nanoparticle Platforms in Cancer Immunotherapy: A Critical Comparative Review of PLGA, Mesoporous Silica, Magnetic Nanoparticles, and Covalent Organic Frameworks.Pharmaceutics · 2026Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- A synergistic strategy of AIE and electron asymmetry anchored in covalent organic frameworks for enhanced periodontitis photodynamic therapy.Materials today. Bio · 2026Article
- Natural panax notoginseng-derived nanovesicles trigger multiple cell death mechanisms and reprogram chemokine signaling to impede oral squamous cell carcinoma progression.Journal of nanobiotechnology · 2026Article
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
- Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation.Frontiers in bioengineering and biotechnology · 2026Review
- Enhanced oral nanomedicine utilizing biomineralized oncolytic virus for synergistic gastrointestinal cancer therapy.Materials today. Bio · 2025Article
- Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities.Journal of hematology & oncology · 2025Review
- An Fe(III)-covalent organic framework (COF)-sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy.Materials today. Bio · 2025Article
- Nature-Inspired Nanostructures from Multiple-Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor-Targeted Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.Materials today. Bio · 2025Review
- Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cellular uptake and tissue dispersion efficiency of nanomedicines are crucial for realizing their biological functionality. As a cutting-edge category of nanomedicine, covalent organic frameworks (COFs)-based photosensitizers, have been extensively employed in cancer phototherapy in recent years. However, the inherent aggregation tendency of COFs hinders their uptake by tumor cells and dispersion within tumor tissues, thereby limiting their therapeutic efficacy. In this study, we employed
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.